Kura Oncology (KURA) Year-over-year earnings per share growth for the last twelve months

Kura Oncology Corp (KURA) - corporate logo

Kura Oncology, Inc. (KURA) is advancing hematologic oncology by leveraging precision cold-chain logistics for global testing. The quarterly EPS growth rate illustrates how valuation depends on the status of breakthrough therapies, where the 7.70 mark serves as the current benchmark. The company's financial stability is currently based on preparations for the launch of a targeted leukemia drug and strict control over commercial scaling.

Kura Oncology (KURA) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 11/18/2026

KURA (kuraoncology.com): analytical breakdowns and indicator data

- market value and analyst target forecast:
Summary company analytics:Kura Oncology Inc - KURA
Finished products of Kura Oncology, Inc.

A defensive portfolio is constructed through rigorous screening of a business's real yield. This indicator measures the percentage change in net income per share between the current and previous quarters. For Kura Oncology, Inc. (KURA), this metric reflects the investment efficiency in developing targeted cancer molecules. Growth in this figure confirms the commercial viability of the company's genetic innovations. Quarterly net income per share dynamics objectify financial results by stripping away market noise.

Competitor analysis

tgtherapeutics.com (TGTX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Arcellx Therapeutics (ACLX)|Year-over-year earnings per share growth for the last twelve months Disc Medicine Inc|Earnings per share growth in annualized terms for the last twelve months Syndax Pharmaceuticals SNDX|Quarterly EPS earnings growth ADCT|Foghorn Therapeutics Inc. - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months vorbio.com VOR|NKTX: Year-over-year earnings per share growth for the last 12 months|COEP - Year-over-year earnings per share growth for the last twelve months|Actinium Pharmaceuticals, Inc. (ATNM) - Year-over-year net earnings per share growth for the last 12 months|ESLA (Estrella Immunopharma) - Year-over-year net earnings per share growth for the last 12 months|CASI - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Marker Bio|Quarterly EPS earnings growth IN8bio, Inc.|Year-over-year earnings per share growth for the last twelve months Eterna Therapeutics Inc (ERNA)|Year-over-year net earnings per share change for the last twelve months gtbiopharma.com|Quarterly EPS earnings growth APTO (Aptose Biosciences)|Quarterly EPS earnings growth Bio-Path BPTH|MEI Pharma Inc - Quarterly EPS earnings growth|VINC (Vincerx Pharma Inc.) - Year-over-year earnings per share growth for the last 12 months